Literature DB >> 28522277

[Immunotherapy and radiotherapy].

S Bockel1, D Antoni2, É Deutsch3, F Mornex4.   

Abstract

Radiotherapy, primarily known for its cytotoxic effect on the tumor cells, via the induction of DNA damages, has the ability to induce a systemic antitumoral response. By an immunologic cell death, tumor cells exposed to radiation release a large amount of neoantigenes and pro-inflammatory mediators, acting as an in situ vaccine, resulting in an tumor regression within the primary irradiated site, but also in the distant "out of field" secondary tumors. However, this phenomenon is extremly rare with radiotherapy alone, suggesting that the radiation-induced antitumor immunity is not sufficient for overcoming the tumor's and its microenvironnement immunosuppressing effect. Over the last years, many scientific data and preclinical studies have demonstrated that the combination of local irradiation with immune therapy has a synergistic action in inducing an antitumoral immunity, thus enhancing an abscopal effect. In this article, we summarize the main mechanisms cancer harnesses to evade the control of the immune system and how ionising radiations can induce an antitumor immunity. A focus reports then on recent preclinical and clinical research built on this background of combined radiation and immune therapy, which bear the great potential to further improve anticancer therapies.
Copyright © 2017. Published by Elsevier SAS.

Entities:  

Keywords:  Abscopal; Immunotherapy; Immunothérapie; Radiotherapy; Radiothérapie

Mesh:

Year:  2017        PMID: 28522277     DOI: 10.1016/j.canrad.2016.12.005

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  8 in total

Review 1.  Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?

Authors:  Roger Sun; Théophraste Henry; Adrien Laville; Alexandre Carré; Anthony Hamaoui; Sophie Bockel; Ines Chaffai; Antonin Levy; Cyrus Chargari; Charlotte Robert; Eric Deutsch
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

Review 2.  Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment.

Authors:  Chen Chen; Yanlong Liu; Binbin Cui
Journal:  Hum Vaccin Immunother       Date:  2021-01-11       Impact factor: 3.452

Review 3.  Radiotherapy and immune response: the systemic effects of a local treatment.

Authors:  Heloisa de Andrade Carvalho; Rosangela Correa Villar
Journal:  Clinics (Sao Paulo)       Date:  2018-12-10       Impact factor: 2.365

Review 4.  Personalized cancer neoantigen vaccines come of age.

Authors:  Yanhong Chu; Qin Liu; Jia Wei; Baorui Liu
Journal:  Theranostics       Date:  2018-07-30       Impact factor: 11.556

Review 5.  Immune targets in the tumor microenvironment treated by radiotherapy.

Authors:  Omer M Ozpiskin; Lu Zhang; Jian Jian Li
Journal:  Theranostics       Date:  2019-01-30       Impact factor: 11.556

Review 6.  Dose-Response Effect and Dose-Toxicity in Stereotactic Radiotherapy for Brain Metastases: A Review.

Authors:  Maxime Loo; Jean-Baptiste Clavier; Justine Attal Khalifa; Elisabeth Moyal; Jonathan Khalifa
Journal:  Cancers (Basel)       Date:  2021-12-02       Impact factor: 6.639

7.  Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.

Authors:  He Huang; Cai-Ping Nie; Xiu-Feng Liu; Bin Song; Jian-Hui Yue; Jing-Xiao Xu; Jia He; Kui Li; Yan-Ling Feng; Ting Wan; Min Zheng; Yan-Na Zhang; Wei-Jun Ye; Jun-Dong Li; Yan-Fang Li; Jun-Yun Li; Xin-Ping Cao; Zhi-Min Liu; Xiao-Shi Zhang; Qing Liu; Xi Zhang; Ji-Hong Liu; Jiang Li
Journal:  J Clin Invest       Date:  2022-08-01       Impact factor: 19.456

Review 8.  Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview.

Authors:  Delphine Antoni; Hélène Burckel; Georges Noel
Journal:  Cancers (Basel)       Date:  2021-05-15       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.